Terapêutica anti-retroviral na infecção a VIH (1ª parte)


  • Eugénio Teófilo Interno do Internato Complementar de Medicina Interna, Serviço 3 - Hospital de Santo António dos Capuchos


terapêutica combinada, resis­tência


Faz-se uma breve revisão sobre a imunofisiopa­tologia da infecção pelo VIH. Abordam-se os fár­macos que se encontram em investigação clínica mais avançada e alguns que poderão ter interesse futuro. Destacam-se os compostos actualmente disponíveis para uso clínico, tentando abordar os aspectos que na prática clínica são mais impor­tantes. Referenciam-se ensaios clínicos quanto à eficácia nestas drogas em monoterapia ou combi­ nação.


Não há dados estatísticos.


Werner A, Winskowsky G, Cichutek K et ai. Productive infection of both CD4+ and CD4- human cell lines with HIV-1, HIV-2 and SJV. AIDS 1990; 4: 537.

Ikeuchi K, Kim S, Byrn RA et al. Infection of non lymphoid cells by human immunodeficiency virus type l or type 2. J Virol 1990; 64: 4226.

Clapham PR, Weber JN, Whitby D et al. Solube CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature 1989; 337 1989.

Cao Yz, Friedman-Kien, Haung YX et al. CD4-independent, productive human immunodeficiency virus type 1 infection of hepatoma cell lines in vitro. J Virol 1990; 64: 2553.

Levy JA. HIV pathogenesis and long-term survival. AIDS 1993; 7: 1401-1410.

Lafeuillade A et ai. High viral burden in Iymph nodes during early stagers of HIV infection. AIDS 1993; 7: 1527.

Howard MT, Bolognesi DP. Where has HIV been hiding? Nature 1993; 362: 292-293.

Pantaleo G et al. Nature 1993; 362: 355-358.

Nuovo GJ, Becker J, Burk MW et al. ln situ detection of PCR­ amplified HIV-1 nucleic acids in lymph nodes and peripheral blood in patients with asymptomatic HIV-1 infection and ad­ vanced stage AIDS. Journal of AIDS 1994; 7: 916-923.

Ameisen. Programmed cell death (apoptosis) and cell survival regulation: relevance to AIDS and cancer. AIDS 1994; 8: 1197- 1213.

Choremi-Papadopoulou H, Viglis V, Gargalianos P et al. Down­ regulation of CD28 surface antigen on CD4+ and CDS+ T Iym­ phocytes during HIV-1 infection.Journal of AIDS 1994: 7 245-253.

Theodore AC, Kornfeld H, Wallace RP et al. CD4 modulation of noninfected T lymphocytes by HIV-1 envelope glycoprotein gp120: contribution to the immunossupression seen in HIV-1 infection by induction of CD4 and CD3 unresponsiveness. Journal of AIDS 1994; 7: 899-907.

Embretson G et al. Nature 1993; 363: 359-362

Matsuyama T et al. Cytokines and HIV infection: is AIDS a tumor necrosis factor disease. AIDS 1991; 5: 1405-1417.

Gougeon ML, Montagnier L. Apoptosis in AIDS. Science 1993: 260(5112): 1269-1270.

Fauci AS. Immunopathogenesis of HIV infection. Journal of AIDS 1993; 6(6): 655-662.

Weiss RA. How does HIV cause AIDS7 Science 1993; 260(5112): 1273-79.

Pantalaeo G, Graziosi C, Fauci AS. New concepts in the immu­ nopathogenesis of human immunodeficiency virus infecti­on. N Engl J Med 1993; 328(5): 327-335

Epstein FH. The molecular biology of human immunocleficien­cy virus type 1 infection. N Engl J Mecl 1991; 324(5): 308-17.

Beclnarik DP, Folks TM. Mechanisms of HIV Latency. AIDS 1992; 6: 3-16.

Yeni P. Schooley R, Hammer S. Antiretroviral and immune-based therapics: update. AIDS 1993; 7(sup 1): Sl73 -Sl84.

Schooley RT et ai. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann lnt Med 1990; 112: 247-252.

Kahn JO et al. The safety and phramacokineticsod recombinam soluble CD11 ( rCD4) in subjects with the acquired immunode­ficiency syndrome (AIDS) anel AIDS-related complex. Ann lnt Med 1990; 112: 254-261.

Gomatos PJ, Stamatos NM and Schooley RT. Soluble Cd4, Immu­ nomodulators, lmmmunotoxins and other Approaches to Anti­ lllV Therapy. in ele Vila ed AIDS: Etiology, Diagnosis, Treat­ ment anel Prevention 1992, JB Lippincott.

Capon DJ. Ward RH. Antiviral effects of CD4 derivatives. Curr Opi lmmunol 1990; 2.433.

Traunecker A, Schncicler J, Kiefer H et al. Highly efficienr neu­tralization of HIV recombinant CD4-immunoglobulin mole­ cules. Nature 1989; 339: 68.

Byrn RA. Meordenti J Lucas C et al. Biological properties of im­munoadhesin. Nature 1990; 344: 667.

Matsushita S, Koito A, Maecla Y et ai. Selective killing of HJV­ infected cells by anti gpl20 immunotoxins. A!Ds Res Hum Retroviruses 1990; 6: 193.

Focus on Diclanosine. Drugs 1992; 44(1): 100.

Zolla-Pazner S. Gorny MK. Passive immunization for the preventi­on and treatment of HIV infection. AIDS 1992; 6: 1235-1248.

Allaway GP, Ryder AM. Heauclry Ga et al. Synergistic inhibiton of HIV-1 envelope mediated cell fusion by CD4-based molecu­laes in combination with antibodies to gpl20 or gp41. AIDS Res Hum Retroviruses 1993; 9(7): 581-587.

Lefrere JJ., Vittecoq D. and the French Passive lmmunotherapy Collaborative Study Group; resumo 050 - 4th European Con­ference on Clinicai Aspects and Treatment of HIV Infection, Milão - Março 94.

Osther K et al. Passhiv-1 treatment of patients with HIV-1 infec­tion. A preliminary report of a Phase I trial hyperimmune porcine immunoglobulin to HIV-1. AIDS 1992; 6: 1457-1465.

-1. Burger Dtvf et al. Drug interactions with zidovudine. AIDS 1993; 7 445-460.

Fischl MA. State of antiretroviral therapy with zidovudine. AIDS 1989: 3(suppl 1) Sl37-Sl41

Richman DD. Aziclothimicline anel other deoxynucleoside ana­ logues. in ele Vita ed AIDS: Etiology, Diagnosis, Treatment and Prevention 1992. JB Lippincott.

Wood AJJ. Therapy for human immunodeficiency virus infecti­on. N Engl J Med 1993: 328: 1686-1695.

Gray F et al. Zidovudine therapy and HIV encephalitis: a 10- year neuropathological survey: AIDS 1994; 8: 489-494.

Hurger DM et al. Penetration of zidovudine into the cerebrospi­nal fluid of patients infected with HIV. AIDS 1993; 7: 1581 - 1588.

Stricker RB, Elswood BF. lmmunosupressive effect of zidovudi­ne ( letter). Ann Int Med 1993; 118: 571-572.

-!1. Mcleod GX. I lammer SM. Immunossupressive effect of zidovu­dine (response). Ann lnt Med 1993; 118: 572.

Roques P. et al. Correlation between HIV provirus burden and in utero transmission. AIDS 1993: 7(sup): S39-S43.

Rouzioux C. et al. Timimg of mother-to-child HIV-1 transmission depends on maternal status. AIDS 1993; 7(sup): S49-S52.

European Collaborative Study. Caesarean section and the risk of vertical transmission of HIV. Lancet 1994; 343: 1464-1467.

Centers for Disease Control and Prevention. Zidovudine for the prevention of HIV transmission from mother to infant. MMWR 1994; 43: 285-287.

Norclic Medical Research Councils' HIV Therapy Group, Dou­ble blind close-response study of zidovudine in AIDS anel advanced HIV infection. BMJ 1992; 304: 13-17

Van Luzen Schmitzj, Schmitz H et al. Nucleoside analogues sup­ press viral replication in patients with high virus load in vitro but interfere with T-cell blastogenesis in earlier stages of HIV­ infection. Resumo 040 4th European Conference on Clinical Aspects and Treatment of HIV Infection, Milão - Março 94.

Tindall B et al. Administration of zidovudine during primary HIV- 1 infection may be associated with a less vigorous immune response. AIDS 1993; 7: 127.

Aboulker JP, Swart AM. Preliminary analysis of the Concorde trial, Lancet 1993; 341: 889-890.

Concorde coordinating comittee, Concorde: MCR/ANRS rando­mised double-blind controlled trial os immediate and defer­red zidovudine in symptom free HIV infection. Lancet 1994: 343: 871-881.

Lipsky JJ. Concorde Lands. Lancet 1994; 343: 866-867.

Mulcler JW, Cooper DA, Mathiesen L et al. Ziclovudine twice dai­ ly in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo­ controlled study. AIDS 1994; 8: 313-322.

Lenclerking WR, Gelber RD, Cotton DJ et al. Evaluation of the quality of life associated with zidovudine treatment in asymp­ tomatic human immunocleficieny virus infection. N Engl J Med 1994; 330(11): 738-743.

Oddone EZ, Cowper D, Hamilton JD et al. Cosi effectiveness analysis of early zidovudine treatment in HIV infected pati­ents. BMJ 1993; 307: 1322-1325.

Cooper DA, Gatell JM, KroonS et ai. Zidovudine in Persons withA,ymp­ tomatic HIV Infection and CD4+ Cell Count, Greater Than 400 Per Cubic Millimeter. N Engl J Mecl 1993; 329: 297-303.

Lunclgren J, Phillips A, Peclersen C and the AIDS in Europe Study Group. Comparison of the Long-term Prognosis of AIDS Pati­ents Treated and Not Treated with Zidovudine; resumo O35 - 4th European Conference on Clinical Aspects and Treatment of HIV lnfection, Milão - Março 94.

Mannucci MP, Gringeri G, Gatenby P. and the European-Austra­lian Haemophilia Collaborative Study Group. Randomized Douhle-Blind, placebo-Controlled Trial os Twice-Daily Zido­vdline in Asymptomatic Haemophiliacs lnfected with the Human Immunodeficiency Syndrome Virus Type l; resumo 036 - 4th European Conference on Clinical Aspects and Treatment of HIV Infection, Milão - Março 94.

Graham NMH, Zeger SL, Park LP et al. The effects on survival of early treatment of human immunodeficiency syndrome. N Engl J Med 1992: 326: 1037-1042.

Dudley MN, Graham KK, Kaul S et al. Pharmacokinetics of Sta­vucline in Patients with AIDS or AIDS-Related Complex, J lnf Dis 1992; 166 480-485.

Browne MJ, Mayer KH, Chafee SB et al. 2',3'-Diclehydro-2'.3'­ clicleoxythymidine (d4T) in Patients with AIDS or AIDS-Rela­ted Complex: A Phase 1 Trial. J lnf Dis 1993: 167: 21-29.

l. Hitchcock MJM. 2',3'-Didehydro-2',3'-dideoxythymidine (cl4Tl, an anti-HIV agent. Ant Chem & Chemot 1991: 2(3): 125-132.

Bret-smith fl. Griffith B, MellorsJ et al. Effect of d4T in HIV Vire­ mia. Abstract PoB301 l, Vlll lnternational Conference on AIDS, Amsterelam 1992.

Dudley MN, Horton C, Kaul S et al. Effect of Dose and Schedule on CD4 Cell lncrease with Stavudine (d4T): an lntegrated Pharma­ cokinetic and Pharmacoelynamic Analysis. Abstract PoB3016, VJJ International Conference cm AIDS, Amsterelam 1992.

Squires K, Sacks H, Sledz S et al. Fiindings from a Phase I Study of Stavudine (el4T). Abstract PoB3030, VIIJ International Con­ference on AIDS, Amsterdam 1992.

Knupp CA, Shyu WC, Dolin Retal. Pharmacokinetics of didano­sine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin Pharm Ther 1991: 49: 523-525.

Groopman JE, MolinaJM. Nucleoside therapy for HIV infection - some answers. many questions. N Engl J Med 1992; 327: 639- 11.

Cooley TP. Kunches LM, Saunders CA et al. Treatment of AIDS and AIDS-related Complex with 2',3'-dideoxyinosine given once daily. Rev of lnf Dis 1990: 12(suppl 5): S552-S560.

Focus on Didanosine, Drugs 1992; 44(1): 108 (tabela).

Connolly KJ, AllanJD, Fitch H et al. Phase J study of 2',3'-dideo­ xyinosine adminstered orally twice daily in patients with AIDS or AIDS-related complex and haematological intolerance to zielovudine. Am J Med 1991; 91: 471-478.

Smaldone L. Beltangady M, Lagakos S et al. The relative safety of didanosine and zidovudine in the ACTG 1116B/117 -Arando­mized double-blind trial. Abstract PoB3007 VII International conference on AIDS, Amsterdam 1992.

McLeod G, Mayers D, McCutchan Fetal. Dideoxynucleoside resistance patterns in clinical isolares of HIV-1. Abstract ThA 1569. VII International conference on AIDS. Amsterdam 1992.

Kozal MJ. Merigan TC. Therpay of HIV-1 Infection, Curr Opin lnf Dis 1994; 7: 72-81.

!,. Merigan TC, Skowron G, Bozzette SA et al. Circulating p24 anti­gen levels anel responses to elideoxycitidine in human immu­nodeficiency virus (HIV) infections. A phase 1/11 study. Ann lnt Med 1989; 110: 189-194.

Merigna TC, Skowron G. elelC study group of the AIDS Clinicai Trials Group od the National lnstitute of Allergy and lnfectious Diseases. Safety and tolerance of clideoxycitidine as a single agent. Results of early-phase studies in patients with acquired immunodeficiency syndrome (AIDS) or advanced AlDS-rela­ ed complex. Am J Int Meel 1990; 88(suppl 5Bl: Sl 1-Sl 5.

Roland T, Katlama C, Berlureau P et al. Long-Term Follouw-up of Patients Treated with Lamivudine (3TC) for Asymptomatic or Milelly Symptomatic HIV Infection; resumo P263 - 4th Eu­ ropean Conference on Clinical Aspects anel Treatment of HIV lnfection, Milão - Março 94.

Van Leeuwen R et al. The Safety and Pharmacokinetics of a Re­verse Transcriptase Inhibitor, 3TC, in Patients with HIV-1 ln­fection: a Phase I Study. AIDS 1992; 6: 1471-1476.

Sommaelossi JP. Nucleosiele analogs: similarities and differenci­es. Clin Infec Dis 1993; 16(sup n S7-S15.

De Jong M, Vella S, Cooper D et al. Neveripine Monotherapy in Nucleoside Naive p24 Antigen Positive Patients: resumo P270

- 4th European Conference on Clinical Aspects and Treatment of HIV lnfection, Milão - Março 94.

Koup RA, Brewster F, Grob P et al. Neviripine synergistically inhibits HIV-1 replication in combination with zielovudine. interferon or CD4 immunoadhesins. AIDS 1993: 7: 1181-1184.

Staszewky S. personal communication AIDS and Medication, 3rd european Meeting on Triais, Drugs and Treatment, Berlin 1993.

Staszewky S, Vandercam B, de Vuyst H et al. Evaluation of the Efficacy and Tolerance of R 18 839, R 89439 (Loviridel anel Placebo in Patients Infected with HIV-1. An lnterim Analysis: resumo 041 - 4th European Conference on Clinical Aspects and Treatment of HIV Infection, Milão - Março 94.

De Braneler M, Staszewsky S, Roeis V et al. Double-Blind eva­luatin of the Effects of R 18839. R 89439 and Placebo on immunological Parameters in Asymptomatic HIV Seropo­sitive Subjects; resumo P266 - 4th European Conference on Clinical Aspects and Treatment of HIV Infection. Mi­lão - Março 94.

Foscarnet Therapy in persons with AIDS: Clinical Research and Management Considerations; J of AIDS,1992; 5: suppl 1.

Focus on foscarnet. Drugs 1991; 41(1): 108-115.

Ficheiros Adicionais



Como Citar

Teófilo E. Terapêutica anti-retroviral na infecção a VIH (1ª parte). RPMI [Internet]. 30 de Setembro de 1994 [citado 23 de Julho de 2024];1(3):169-82. Disponível em: https://revista.spmi.pt/index.php/rpmi/article/view/2469



Artigos de Revisão